http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12253740

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't
endingPage 419
issn 0925-5710
1865-3774
issueIdentifier 4
pageRange 409-419
publicationName International Journal of Hematology
startingPage 409
bibliographicCitation Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. International Journal of Hematology. 2012 Feb 23;95(4):409–19. doi: 10.1007/s12185-012-1026-9.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ebd146d9783a6aa796e1efa263f552d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1649adeb29752891c7abe93a28b79db8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5f5d679b38b1d66615df57d24b4f526
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_69879abcf2b81bc92a8bdc4ec5a51a6a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e4041b498bf51be520cd57188ccc3c52
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_873b19f54fbc407dcaa01838e38fe04e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5dbbfabe9f108007b7326fc521a220ce
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dd1f80026f41f60e9d4c4f67a8a8ee08
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c3acf70d1701ec4aba07910d89a8d16
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4018dfeea1198855a1494c1d720a685a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0e1548086c915b479ea5020433d7140b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e31e04d22aad3c5411f1698b4ef4dbf7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1b88e244722cdb4438acea26aea5c108
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c892cbe719fdbd9c08f179a759e7c77
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3f12b6ec8dfa106684b2877c3552b7c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7e9bc671e2fc345016eb332c2a2add46
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37d8cc17c218a73bb9cc35985c2b5859
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffdd398663503cef3daea4cb60b28777
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_42d2e6aefe17c7fdce0ee63f69983b92
date 2012-02-23^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/22359103
https://doi.org/10.1007/s12185-012-1026-9
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1221
https://portal.issn.org/resource/ISSN/1865-3774
https://portal.issn.org/resource/ISSN/0925-5710
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://scigraph.springernature.com/
https://www.crossref.org/
title Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study
discusses http://id.nlm.nih.gov/mesh/M0482811
http://id.nlm.nih.gov/mesh/M0457532
http://id.nlm.nih.gov/mesh/M0017888
http://id.nlm.nih.gov/mesh/M0024527
http://id.nlm.nih.gov/mesh/M0018260
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D054198Q000188
http://id.nlm.nih.gov/mesh/D011743Q000627
http://id.nlm.nih.gov/mesh/D047428Q000627
http://id.nlm.nih.gov/mesh/D011505Q000037
http://id.nlm.nih.gov/mesh/D015464Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D055815
http://id.nlm.nih.gov/mesh/D000369
http://id.nlm.nih.gov/mesh/D011743Q000009
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D044466Q000235
http://id.nlm.nih.gov/mesh/D047428Q000009
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D009154Q000187
http://id.nlm.nih.gov/mesh/D054198Q000235
http://id.nlm.nih.gov/mesh/D020732
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D016044Q000235
http://id.nlm.nih.gov/mesh/D015464Q000235
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID644241
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8592
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11043
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7660
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9729

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247851103
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128433595
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459

Showing number of triples: 1 to 82 of 82.